Philippe Charron

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/3248721/philippe-charron-publications-by-year.pdf
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

36 papers	6,897 citations	20 h-index	44 g-index
44 ext. papers	8,721 ext. citations	7.7 avg, IF	4.94 L-index

#	Paper	IF	Citations
36	Generation of a heterozygous SCN5A knockout human induced pluripotent stem cell line by CRISPR/Cas9 edition.. *Stem Cell Research*, **2022**, 60, 102680	1.6	
35	Assessment of atrial function by myocardial deformation techniques in hypertrophic cardiomyopathy. *Echocardiography*, **2021**, 38, 230-237	1.5	0
34	Genome-wide association analysis in dilated cardiomyopathy reveals two new players in systolic heart failure on chromosomes 3p25.1 and 22q11.23. *European Heart Journal*, **2021**, 42, 2000-2011	9.5	14
33	Generation of iPSC line from MYH7 R403L mutation carrier with severe hypertrophic cardiomyopathy and isogenic CRISPR/Cas9 corrected control. *Stem Cell Research*, **2021**, 52, 102245	1.6	2
32	Phenotype/Genotype Relationship in Left Ventricular Noncompaction: Ion Channel Gene Mutations Are Associated With Preserved Left Ventricular Systolic Function and Biventricular Noncompaction: Phenotype/Genotype of Noncompaction. *Journal of Cardiac Failure*, **2021**, 27, 677-681	3.3	2
31	Differences between familial and sporadic dilated cardiomyopathy: ESC EORP Cardiomyopathy & Myocarditis registry. *ESC Heart Failure*, **2021**, 8, 95-105	3.7	4
30	A novel risk model for predicting potentially life-threatening arrhythmias in non-ischemic dilated cardiomyopathy (DCM-SVA risk). *International Journal of Cardiology*, **2021**, 339, 75-82	3.2	0
29	Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect. *Nature Genetics*, **2021**, 53, 128-134	36.3	35
28	Global and regional echocardiographic strain to assess the early phase of hypertrophic cardiomyopathy due to sarcomeric mutations. *European Heart Journal Cardiovascular Imaging*, **2020**, 21, 291-298	4.1	5
27	Clinical Profile of Cardiac Involvement in Danon Disease: A Multicenter European Registry. *Circulation Genomic and Precision Medicine*, **2020**, 13, e003117	5.2	10
26	Psychosocial Impact of Predictive Genetic Testing in Hereditary Heart Diseases: The PREDICT Study. *Journal of Clinical Medicine*, **2020**, 9,	5.1	3
25	Higher prevalence of splenic artery aneurysms in hereditary hemorrhagic telangiectasia: Vascular implications and risk factors. *PLoS ONE*, **2020**, 15, e0226681	3.7	2
24	Mid-regional proatrial natriuretic peptide for predicting prognosis in hypertrophic cardiomyopathy. *Heart*, **2020**, 106, 196-202	5.1	3
23	Clinical impact of post-mortem genetic testing in cardiac death and cardiomyopathy. *Open Medicine (Poland)*, **2020**, 15, 435-446	2.2	2
22	The Public Health Burden of Cardiomyopathies: Insights from a Nationwide Inpatient Study. *Journal of Clinical Medicine*, **2020**, 9,	5.1	4
21	FLNC pathogenic variants in patients with cardiomyopathies: Prevalence and genotype-phenotype correlations. *Clinical Genetics*, **2019**, 96, 317-329	4	29
20	The Cardiomyopathy Registry of the EURObservational Research Programme of the European Society of Cardiology: baseline data and contemporary management of adult patients with cardiomyopathies. *European Heart Journal*, **2018**, 39, 1784-1793	9.5	60

19	Clinical Diagnosis, Imaging, and Genetics of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: JACC State-of-the-Art Review. *Journal of the American College of Cardiology*, **2018**, 72, 784-804	15.1	105
18	Pregnancy in women with a cardiomyopathy: Outcomes and predictors from a retrospective cohort. *Archives of Cardiovascular Diseases*, **2018**, 111, 199-209	2.7	20
17	Hypertrophic obstructive cardiomyopathy. *Lancet, The*, **2017**, 389, 1253-1267	40	117
16	Natural genetic variation of the cardiac transcriptome in non-diseased donors and patients with dilated cardiomyopathy. *Genome Biology*, **2017**, 18, 170	18.3	40
15	Role of Genetic Testing in Inherited Cardiovascular Disease: A Review. *JAMA Cardiology*, **2017**, 2, 1153-1160	16.2	45
14	Exome-wide association study reveals novel susceptibility genes to sporadic dilated cardiomyopathy. *PLoS ONE*, **2017**, 12, e0172995	3.7	66
13	Long-Term Arrhythmic and Nonarrhythmic Outcomes of Lamin A/C Mutation Carriers. *Journal of the American College of Cardiology*, **2016**, 68, 2299-2307	15.1	148
12	Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. *European Heart Journal*, **2016**, 37, 1850-8	9.5	473
11	European Cardiomyopathy Pilot Registry: EURObservational Research Programme of the European Society of Cardiology. *European Heart Journal*, **2016**, 37, 164-73	9.5	42
10	Involvement of BAG3 and HSPB7 loci in various etiologies of systolic heart failure: Results of a European collaboration assembling more than 2000 patients. *International Journal of Cardiology*, **2015**, 189, 105-7	3.2	18
9	Genetic advances in sarcomeric cardiomyopathies: state of the art. *Cardiovascular Research*, **2015**, 105, 397-408	9.9	151
8	2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). *European Heart Journal*, **2014**, 35, 2733-79	9.5	2361
7	A genome-wide association study identifies 6p21 as novel risk locus for dilated cardiomyopathy. *European Heart Journal*, **2014**, 35, 1069-77	9.5	97
6	A genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathy. *European Heart Journal*, **2011**, 32, 1065-76	9.5	228
5	Early identification of mutation carriers in familial hypertrophic cardiomyopathy by combined echocardiography and tissue Doppler imaging. *European Heart Journal*, **2010**, 31, 1599-607	9.5	30
4	Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. *European Heart Journal*, **2008**, 29, 270-6	9.5	1641
3	Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. *Circulation*, **2003**, 107, 2227-32	16.7	924
2	Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene. *Circulation*, **1998**, 97, 2230-6	16.7	196

1 Genome wide association analysis in dilated cardiomyopathy reveals two new key players in systolic heart failure on chromosome 3p25.1 and 22q11.23 1